You are here
Orphan drug designation prior to 1 July 2017
6 July 2018
The content on this web page applies to orphan drug designation applications lodged prior to 1 July 2017 under the previous program. Orphan designations under the previous program will remain published on this website, but will no longer be in force after the transition period ends on 1 July 2018 (unless any relate to pending applications as at 1 July 2017 where a transition of 12 months applies from the day the designation came into force).
Please see Orphan drug program reforms for information on the changes to the orphan drug program effective from 1 July 2017.
Amendments to the Therapeutic Goods Regulations 1990 which came into effect on 1 July 2017 changed the eligibility criteria for Orphan drug designation. All designated Orphan drugs in the tables below were submitted to the TGA before 1 July 2017 and were assessed against the eligibility criteria that were relevant at the time of lodging the designation application.
For more detail on the eligibility criteria that were applicable, please see section 16H of the Therapeutic Goods Regulations 1990 (and refer to the superseded versions with start dates prior to 1 July 2017).
Designated orphan drugs prior to 1 July 2017
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| 5-aminolevulinic acid hydrochloride (Gliolan) | Specialised Therapeutics Australia Pty Ltd | 30/03/12 | Powder for oral solution | Gliolan is indicated for photodynamic diagnosis of gliomas that are glioblastoma multiforme (GBM) (malignant) on preoperative imaging, and intended for gross macroscopic resection of all visible tumour. |
| 5-azacytidine | Pharmion Pty Ltd | 02/09/04 | For the treatment of myelodysplastic syndrome. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| 6-chloro-2, 3, 4, 9-tetrahydro-1H-carboxamide | Siena Biotech Italy | 11/03/11 | For the treatment of Huntington's Disease. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Adalimumab (Humira) | AbbVie Pty Ltd | 19/08/15 | Solution for injection |
For the treatment of adult patients with non-infectious intermediate, posterior or pan-uveitis who have an inadequate response to corticosteroid therapy or who relapse when corticosteroid therapy is tapered down. |
| Adalimumab (HUMIRA) | AbbVie Pty Ltd | 30/01/15 | Solution for injection |
For the treatment of paediatric Enthesitis-Related Arthritis (paediatric ERA). |
| Adalimumab (HUMIRA) | Abbott Australasia Pty Ltd | 16/01/12 | Solution for injection | For the treatment of active Crohn's Disease defined as a Paediatric Crohn's Disease Activity Index (PCDAI) score >30 in paediatric patients (6-17 years of age) who have had an inadequate response to conventional therapy, or who are intolerant to or have contraindications for such therapies. |
| Adalimumab (HUMIRA) | AbbVie Pty Ltd | 02/11/12 | Solution for injection | For the treatment of active Crohn's Disease defined as a Paediatric Crohn's Disease Activity Index (PCDAI) score >30 in paediatric patients (6-17 years of age) who have had an inadequate response to conventional therapy, or who are intolerant to or have contraindications for such therapies. |
| Adefovir dipivoxil | Gilead Sciences Pty Ltd | 12/08/05 | In monotherapy or in combination with other therapies, for prevention of recurrence of HBV infection in liver transplant recipients. | |
| Adefovir dipivoxil (HEPSERA) | Gilead Sciences Pty Ltd | 30/10/08 | 10mg oral tablets | For the treatment of chronic hepatitis B in adolescent patients (12 to |
| Afamelanotide (SCENESSE) | Clinuvel Pharmaceuticals Ltd | 08/11/10 | Subcutaneous implant | For the treatment of erythropoietic porphyrias. |
| Afatinib | Boehringer Ingelheim Pty Limited | 01/06/12 | Tablets | For the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) mutation (s). |
| Agalsidase alfa (REPLAGAL) | PPD Australia Pty Limited | 20/10/00 | For the long-term enzyme replacement therapy in patients with Fabry disease. | |
| Agalsidase beta (FABRAZYME) | Genzyme Australasia Pty Ltd | 22/05/00 | For long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry Disease. | |
| Aimspro (Goat Serum Derived Product) | Daval Australia Pty Ltd | 22/08/05 | For treatment of Krabbe's Disease (Globoid Cell Leucodystrophy). | |
| Albutrepenonacog Alfa | CSL Behring Australia Pty Ltd | 27/10/14 | Injection |
For the treatment and prophylaxis of bleeding associated with congenital factor IX deficiency (haemophilia B). |
| Aldesleukin (PROLEUKIN) | CSL Limited | 16/10/98 | For the treatment of metastatic renal cell carcinoma. | |
| Aldesleukin (PROLEUKIN) | CSL Limited | 16/10/98 | To treat metastatic melanoma. | |
| Alectinib | Roche Products Pty Limited | 27/10/15 | Capsule |
For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer. |
| Algucosidase alfa (MYOZYME) | Genzyme Australasia Pty Ltd | 08/09/03 | Powder for concentrate for solution for infusion | For the treatment of Pompe disease (glycogen storage disease type II). |
| Alpha-1-proteinase inhibitor (GLASSIA) | Baxter Healthcare Pty Ltd | 03/07/12 | Solution for IV injection | For the treatment of chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1-antitrypsin. |
| Ambrisentan | GlaxoSmithKline Australia Pty Ltd | 05/07/07 | Tablets 5 mg & 10 mg | For the treatment of patients with pulmonary arterial hypertension (PAH) to improve exercise capacity, delay clinical worsening and decrease the symptoms of PAH. |
| Amikacin Sulfate | Novotech (Australia) Pty Limited | 26/02/15 | Suspension for inhalation |
For the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older. |
| Anagrelide hydrochloride (AGRYLIN) | Orphan Australia Pty Ltd | 16/10/98 | For the treatment of essential thrombocytosis. | |
| Anagrelide Hydrochloride (THROMBOREDUCTIN) | Max Pharma Ptd Ltd | 26/05/08 | Capsules |
For the treatment of essential thrombocythaemia in patients with high or immediate risk of thrombosis or bleeding. |
| Anagrelide hydrochloride (Thromboreductin) | Orphan Australia Pty Ltd | 23/04/09 | 0.5mg and 1.0mg capsules |
For treatment of essential Thrombocythaemia in patients with high or intermediate risk of thrombosis or bleeding. |
| Anakinra (KINERET) | Invida Australia Pty Ltd | 20/12/11 | Solution for injection | For the treatment of active systemic onset juvenile idiopathic arthritis (SoJIA) in children. |
| Anakinra (KINERET) | Invida Australia Pty Ltd | 08/05/13 | Solution, pre-filled syringe 100 mg / 0.67 mL | For the treatment of cryopyrin associated periodic syndromes (CAPS) in adults and children including: Muckle-Wells syndrome (MWS) Familial cold-induced autoinflammatory syndrome (FCAS)/familial cold urticaria (FUC) Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological cutaneous and articular syndrome (CINCA) |
| Andepatuzumab mafodotin | AbbVie Pty Ltd | 15/09/16 | Lyophylised powder for injection |
For the treatment of glioblastoma multiforme. |
| Anti-H5N1 | Clinical Network Services Pty Ltd | 12/02/14 | Solution for infusion | Passive immunotherapy in case of post-exposure or suspected post-exposure to H5N1 avian influenza virus. |
| Arsenic Trioxide | Phebra Pty Ltd | 16/03/17 | Capsule |
For the treatment of Acute Promyelocytic Leukaemia (APL). |
| Arsenic trioxide | Phebra Pty Ltd | 24/02/11 | Tablets and oral liquid | For the treatment of acute promyelocytic leukaemia. |
| Arsenic trioxide injection | Pharmalab Pty Limited | 21/08/03 | For the treatment of patients with acute promyelocytic leukaemia, who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy. | |
| Arsenic trioxide injection | Pharmalab Pty Limited | 08/06/04 | For the treatment of patients with acute promyelocytic leukaemia. | |
| Artemether and lumefantrine (RIAMET) | Novartis Pharmaceuticals Australia Pty Limited | 27/10/99 | For the treatment of children and adults with infections due toPlasmodium falciparum or mixed infections including P falciparum. | |
| Artesunate injection | Link Pharmaceuticals trading as Link Medical Products Pty Ltd | 17/01/07 | Solution for injection | For the treatment of severe malaria including cerebral malaria and as a second line treatment in chloroquine resistant malaria cases. |
| Asfotase alfa | Alexion Pharmaceuticals Australasia Pty Ltd | 15/10/12 | Subcutaneous injection | For the treatment of hypophosphatasia (HPP). |
| Ataluren (TRANSLARNA) | Link Medical Products Pty Ltd | 17/07/15 | Granules |
For the treatment of patients with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene. |
| Avelumab | Merck Serono Australia Pty Ltd | 27/07/16 | Concentrated solution for intravenous infusion |
For the treatment of Merkel Cell Carcinoma. |
| Axitinib | Pfizer Australia Pty Ltd | 14/04/11 | Tablets | For the treatment of advanced renal cell carcinoma (RCC). |
| Azacytidine (VIDAZA) | Celgene Pty Ltd | 17/06/08 | Powder for suspension for injection | For the treatment of myelodysplastic syndrome. |
| Aztreonam lysine | Gilead Sciences Pty Ltd | 16/07/07 | Single-use 1 mL vial containing 75 mg aztreonam and 52.5 mg lysine lyophilized powder, supplied with a single-use diluent ampoule containing 1 mL sterile water for injection with 0.17% NaCl | Control of gram-negative bacteria, particularly pseudomonas aeruginosa, in the respiratory tract of patients with cystic fibrosis. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Beclometasone dipropionate (ORBEC) | Orphan Australia Pty Ltd | 31/10/08 | Oral capsules containing 1 mg immediate release beclometasone dipropionate tablet and 1 mg enteric-coated beclometasone dipropionate tablet | For the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GVHD) following allogenic haematopoietic cell transplantation in conjunction with an induction course of high-dose prednisone or methylprednisolone. |
| Bevacizumab (AVASTIN) | Roche Products Pty Ltd | 13/01/09 | A concentrated solution for injection - 100mg in 4 mLs and 400 mg in 16 mLs | For the treatment of malignant glioma. |
| Bevacizumab (AVASTIN) | Roche Products Pty Limited | 04/01/17 | Concentrated injection |
For the treatment of malignant mesothelioma. |
| Bevacizumab (AVASTIN) | Roche Products Pty Ltd | 21/03/14 | Injection, concentrated |
For the treatment of persistent, recurrent or Stage IV carcinoma of the cervix. |
| BicaVera range of sterile peritoneal dialysis solutions | Fresenius Medical Care Australia Pty Ltd | 29/10/02 | For use as a peritoneal dialysis solution in the management of end stage renal disease and acute renal failure. | |
| Blinatumomab | Amgen Australia Pty Ltd | 20/11/13 | Powder for reconstitution, Injection | For the treatment of B-precursor acute lymphoblastic leukemia. |
| Bortezomib (VELCADE) | Janssen-Cilag Pty Ltd | 22/10/03 | Powder for injection | For the treatment of resistant or relapsed multiple myeloma. |
| Bortezomib (VELCADE) | Janssen-Cilag Pty Ltd | 19/08/14 | Powder for injection |
For the treatment of patients with mantle cell lymphoma. |
| Bosentan | Omnicare Clinical Research | 12/02/01 | For the treatment of primary pulmonary hypertension or pulmonary hypertension secondary to scleroderma, in patients meeting WHO criteria for inclusion in functional class III-IV pulmonary hypertension. | |
| Bosentan | Actelion Pharmaceuticals Australia Pty Ltd | 02/12/14 | Film coated tablet |
For the treatment of Pulmonary Arterial Hypertension. |
| Bosentan | Amneal Pharma Australia Pty Ltd | 17/05/16 | Film coated tablet |
For the treatment of the following: |
| Bosentan (TRACLEER) | Actelion Pharmaceuticals Australia Pty Ltd | 27/08/10 | 62.5 mg and 125 mg tablets | For the treatment of digital ulcers in patients with systemic sclerosis. |
| Bosutinib | Pfizer Australia Pty Ltd | 13/08/12 | Tablets | For the second or third line treatment of chronic myeloid leukaemia. |
| Brentuximab vedotin (ADCETRIS) | Nycomed Pty Ltd | 17/09/12 | Powder for infusion | For the treatment of: relapsed or refractory Hodgkin lymphoma (HL) and; systemic anaplastic large cell lymphoma (SALCL). |
| Brigatinib (Alunbrig) | Takeda Pharmaceuticals Australia Pty Ltd | 28/07/17 | Film-coated tablet |
For the treatment of patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. |
| Busulfan (BUSULFEX) | Orphan Australia Pty Ltd | 12/10/05 | For use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to haematopoietic progenitor cell transplantation. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| C1 esterase inhibitor (BERINERT P) | CSL Limited | 10/04/07 | Powder for injection | For the treatment of hereditary angioedema. |
| C1 esterase inhibitor (CINRYZE) | Cedarglen Investments Pty Ltd | 15/10/10 | Powder for reconstitution for intravenous administration | For the treatment, routine prevention and pre-procedure prevention of angiodema attacks in adults, adolescents, and children from 6 years of age with C1 inhibitor deficiency. |
| C1 esterase inhibitor, human (Berinert) | CSL Behring Australia Pty Ltd | 10/04/17 | Powder for injection, subcutaneous |
For subcutaneous administration for prophylaxis (routine prevention) of hereditary angioedema (HAE) attacks. |
| Caffeine citrate injection | Ophthalmic Laboratories Pty Limited | 02/08/07 | Solution for injection 40 mg/2mL | For the short term treatment of apnoea of prematurity of gestational age 28 to less than 33 weeks. |
| Caffeine citrate oral solution | Ophthalmic Laboratories Pty Limited | 02/08/07 | 25mg/5mL | For the short term treatment of apnoea of prematurity of gestational age 28 to less than 33 weeks. |
| Canakinumab (ILARIS) | Novartis Pharmaceuticals Australia Pty Limited | 01/05/13 | Powder for Injection | For the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patients aged 2 years and older. |
| Canakunimab (ILARIS) | Novartis Pharmaceuticals Australia Pty Ltd | 30/01/09 | 150mg powder for injection |
For the treatment of Cryopyrin Associated Syndromes (CAPS) in adults and children aged 4 years and older including: |
| Canakunimab (ILARIS) | Novartis Pharmaceuticals Australia Pty Ltd | 12/11/12 | Powder for injection |
For the treatment of Cryopyrin Associated Syndromes (CAPS) in adults and children aged 2 years and older including : |
| Caprine hyperimmune serum against HIV lysate (AIMSPRO) | Daval Australia Pty Ltd | 15/05/09 | 4.5mg total protein/ml liquid for subcutaneous injection | For the treatment of amyotrophic lateral sclerosis. |
| Carboprost as the tropmethamine (HEMABATE) | Pharmacia & Upjohn | 16/10/98 | For the treatment of post-partum haemorrhage due to uterine atony. | |
| Carglumic acid (CARBAGLU™) | Emerge Health Pty Ltd | 13/03/12 | Dispersible tablet | For the treatment of the following: hyperammonaemia due to N-acetylglutamate synthase primary deficiency; hyperammonaemia due to isovaleric acidaemia; hyperammonaemia due to methylmalonic acidaemia and; hyperammonaemia due to propionic acidaemia. |
| Carglumic acid (UCEDANE) | Orpharma Pty Ltd | 11/10/16 | Dispersible tablets |
For the treatment of: |
| Carmustine (GLIADEL) | Orphan Australia Pty Ltd | 25/09/03 | For use as an adjunct to surgery to prolong survival in patients with malignant glioma. | |
| Carmustine implants (GLIADEL wafers) | Rhone-Poulenc Rorer Australia | 16/10/98 | For use as an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated | |
| Catridecacog | Novo Nordisk Pharmaceuticals Pty Ltd | 22/11/11 | Powder for injection | Routine prophylaxis for bleeding in patients with congenital Factor XIII A subunit deficiency. |
| Catumaxomab (REMOVAB) | Biotech Regulatory Solutions | 15/09/10 | Concentrate for solution for infusion | For the treatment of patients with malignant ascites due to EpCAM-positive carcinomas |
| Celecoxib (CELEBREX) | Searle | 10/04/00 | To reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis (FAP), as an adjunct to usual care (eg endoscopic surveillance, surgery). | |
| Ceritinib (ZYKADIA) | Novartis Pharmaceuticals Australia Pty Ltd | 01/09/14 | Hard capsule |
For the treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive. |
| Chenodeoxycholic acid | Link Healthcare Pty Ltd | 24/02/16 | Capsule |
For the treatment of inborn errors of primary bile acid synthesis. |
| Chlormethine (VALCHLOR) | Actelion Pharmaceuticals Australia Pty Ltd | 25/03/15 | Topical gel |
For the treatment of cutaneous T cell lymphoma. |
| Cholic acid | Orpharma Pty Ltd | 25/07/13 | oral capsules 50 mg and 250 mg | For the treatment of inborn errors of bile acid synthesis responsive to treatment with cholic acid. |
| Cholic acid (ORPHACOL) | Emerge Health | 04/09/14 | Capsule |
For the treatment of inborn errors of primary bile acid synthesis due to 3β-hydroxy-Δ5-C27-steroid oxidoreductase (3β-HSD) deficiency or Δ4-3-oxosteroid 5β-reductase (Δ4-3-oxoR) deficiency. |
| Cladribine (LITAK) | Orphan Australia Pty Ltd | 23/01/03 | For the treatment of hairy cell leukaemia and lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinaemia). | |
| Clobazam (FRISIUM) | Sanofi-Aventis Australia Pty Ltd | 14/09/09 | Tablet | For the treatment of paediatric refractory epilepsy. |
| Clofarabine (EVOLTRA) | Hospira Australia Pty Ltd | 02/10/07 | Concentrated solution for infusion | For the treatment of acute myeloid leukaemia in adults 60 years of age and over and for the treatment of acute lymphoblastic leukaemia in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens. |
| Colistimethate sodium | Phebra Pty Ltd | 31/10/08 | Sterile lyophilised powder 1MIU and 2MIU (colistimethate base) in single use vials for nebulisation. | For treatment of pseudomonas aeruginosa infections in patients with cystic fibrosis. |
| Combivir | GlaxoSmithKline Australia Pty Ltd | 10/07/07 | Tablets (containing lamivudine 150 mg & zidovudine 300 mg) | For antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected children under 12 years of age. |
| Crizotinib (XALKORI) | Pfizer Australia Pty Ltd | 23/09/16 | Capsule |
For the treatment of ROS1-positive non-small cell lung cancer (NSCLC). |
| Crizotinib (XALKORI) | Pfizer Australia Pty Ltd | 05/09/11 | 200mg and 250mg capsules for oral use |
For the treatment of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). |
| Cyclosporin | Delpharm Consultants Pty Ltd | 17/11/04 | For the prevention of graft rejection of lung transplants. | |
| Cytarabine intrathecal injection (DEPOCYT) | Orphan Australia Pty Ltd | 07/01/04 | 50mg/5mL injection vial | For the treatment of symptomatic neoplastic meningitis. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Dabrafenib | GlaxoSmithKline Australia Pty Ltd | 30/05/12 | Capsules | For the treatment of patients with BRAF V600 mutation positive unresectable or metastatic (Stage IV) melanoma. |
| Darunavir (PREZISTA) | Janssen-Cilag Pty Ltd | 22/08/08 | 75 mg, 150 mg, 300 mg and 600 mg tablet | For the treatment of HIV infection in paediatric patients (children and adolescents aged 6 to |
| Dasatinib (SPRYCEL) | Bristol-Myers Squibb Pharmaceuticals Pty Ltd | 12/10/05 | Tablets | For the treatment of chronic myeloid leukaemia in patients who are resistant to or intolerant of imatinib. For Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL). |
| Decitabine (DACOGEN) | Janssen-Cilag Pty Ltd | 16/10/12 | Injection | For the treatment of adult patients ≥65 years with newly diagnosed de novo or secondary acute myeloid leukaemia (AML). |
| Defactinib | Plunkett Consulting Pty Ltd | 24/11/14 | Tablet |
For the treatment of malignant mesothelioma. |
| Deferasirox (EXJADE) | Novartis Pharmaceuticals Australia Pty Limited | 24/09/04 | Dispersible tablets | For the treatment of chronic iron overload in patients with transfusion-dependent anaemias. |
| Deferiprone (FERRIPROX) | Orphan Australia Pty Ltd | 22/05/01 | For the treatment of iron overload in patients with thalassaemia major, unwilling or unable to take desferrioxamine therapy. | |
| Defibrotide | Link Healthcare | 12/11/13 | Concentrate for solution for infusion | For the treatment of hepatic veno-occlusive disease (VOD). |
| Denosumab (XGEVA) | Amgen Australia Pty Ltd | 27/06/14 | Solution for injection | For the treatment of hypercalacaemia of malignancy that is refractory to intravenous bisphosphonates. |
| Denosumab (XGEVA) | Amgen Australia Pty Ltd | 03/10/12 | Injection | For the treatment of patients with giant cell tumours of the bone. |
| Deutetrabenazine | Teva Pharma Australia Pty Ltd | 09/05/16 | Film-coated tablets |
For the treatment of chorea associated with Huntington's disease. |
| Dexamethasone (Ozurdex) | Allergan Australia Pty Ltd | 12/04/17 | Intravitreal implant |
For the treatment of non-infectious uveitis affecting the posterior section of the eye. |
| DEXPRAMIPEXOLE | Biogen Idec Australia Pty Ltd | 25/10/11 | Tablets | For the treatment of amyotrophic lateral sclerosis (ALS). |
| Dichlorphenamide (Keveyis) | Ranbaxy Australia Pty Ltd | 02/08/16 | Tablet |
For the treatment of primary periodic paralysis. |
| Digoxin-Specific Anitbody Fragment F(Ab) (Ovine) | Phebra Pty Ltd | 19/05/11 | Powder for injection |
For the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. |
| Dornase alpha (PULMOZYME) | Roche Products Pty Ltd | 28/04/04 | For the management of demonstrated respiratory complications in cystic fibrosis in children under the age of five years. | |
| Drisapersen | GlaxoSmithKline Australia Pty Ltd | 10/12/13 | Solution for injection | For the treatment of patients with Duchenne muscular dystrophy (DMD) bearing certain mutations that are amenable to treatment with exon 51 skipping. |
| Duodopa (LEVODOPA / CARBIDOPA) | Abbott Products Pty Ltd | 16/12/10 | 20mg/mL and 5mg/mL intestinal gel | For the treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations and not responding to oral treatment. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Ecallantide (KALBITOR) | Link Medical Products Pty Ltd | 13/05/11 | Solution for Injection | For the treatment of patients with hereditary angioedema. |
| Eculizumab (rmc) (SOLIRIS) | Alexion Pharmaceuticals Australasia Pty Ltd | 05/09/11 | Solution for intravenous infusion 300mg in 30 mL vial | For the treatment of atypical haemolytic uraemic syndrome (aHUS). |
| Eculizumab (rmc) (SOLIRIS) | Alexion Pharmaceuticals Australasia | 18/01/17 | Solution for IV infusion |
For the prevention of delayed graft function (DGF) after solid organ transplantation. |
| Eculizumab (SOLIRIS) | Alexion Pharmaceuticals Australasia Pty Ltd | 26/10/12 | Concentrated solution for IV infusion vial | For the treatment of infection - associated haemolytic uraemic syndrome. |
| Eculizumab (SOLIRIS) | Cedarglen Investments Pty Ltd | 10/04/07 | solution for injection E | For the treatment of paroxysmal nocturnal haemoglobinuria. |
| Efavirenz (STOCRIN) | Merck Sharp & Dohme (Australia) Pty Ltd | 31/10/00 | For the treatment of HIV-1 infection in children and adolescents over the age of 3 years. | |
| ELAPRASE idursulfase-rhu Solution For IV Infusion vial | Genzyme Australasia Pty Ltd | 30/06/06 | For the long term treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). | |
| Eliglustat | Sanofi-Aventis Australia Pty Ltd | 02/08/13 | Capsules | The indication is for the treatment of long term treatment of adult patients with Gaucher disease type 1 (GD1) |
| Elosulfase-Alpha | BioMarin Pharmaceutical Australia Pty Ltd | 05/07/13 | Solution for infusion | For the treatment of mucopolysaccharidosis IV type A (Morquio A syndrome, MPS IVA). |
| Eltrombopag (REVOLADE) | GlaxoSmithKline Australia Pty Ltd | 15/07/14 | Tablets |
For the treatment of cytopenias in patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy. |
| Eltrombopag (Revolade) | GlaxoSmithKline Australia Pty Ltd | 29/10/14 | Powder for oral liquid |
For the treatment of chronic idiopathic thrombocytopaenic purpura (ITP). |
| Eltrombopag olamine (REVOLADE) | GlaxoSmithKline Australia Pty Ltd | 17/07/08 | Tablet | For the treatment of idiopathic thrombocytopenic purpura (ITP). |
| Emtricitabine (EMTRIVA) | Gilead Sciences Pty Ltd | 23/03/12 | Tablets |
For the treatment of HIV-! Infection in paediatric patients aged 12 to 17 years inclusive. |
| Epoprostenol (VELETRI) | Actelion Pharmaceuticals Australia Pty Ltd | 17/01/12 | Lyophilized powder for reconstitution | Treatment of pulmonary arterial hypertension. |
| Epoprostenol sodium (FLOLAN) | Glaxo Wellcome Australia Ltd | 06/12/99 | For the long term treatment of primary pulmonary hypertension in New York Heart Association (NYHA) Class III and IV patients. | |
| Epoprostenol sodium (FLOLAN) | GlaxoSmithKline Australia Pty Ltd | 05/04/06 | For the treatment of Pulmonary Arterial Hypertension (PAH) associated with collagen vascular diseases, in New York Heart Association (NYHA) functional class III and class IV patients. | |
| Eptacog alfa (NOVOSEVEN) | Novo Nordisk Pharmaceuticals Pty Ltd | 14/01/05 | For the prevention and treatment of bleeding episodes in patients with congenital Factor VII deficiency or Glanzmann's Thrombasthenia. | |
| Equine Antithymocyte Immunoglobulin (ATGAM) | Pfizer Australia Pty Ltd | 08/10/15 | Injection, solution |
For the treatment of aplastic anaemia. |
| Erlotinib (TARCEVA) | Roche Products Pty Ltd | 14/04/11 | Tablets |
For the treatment of advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations. |
| Ethyl eicosapentaenoate | Orphan Australia Pty Ltd | 15/07/04 | For the treatment of Huntington's Disease. | |
| Everolimus (AFINITOR) | Novartis Pharmaceuticals Australia Pty Limited | 17/07/08 | 5 mg and 10 mg tablets | For the treatment of advanced renal cell carcinoma (RCC). |
| Everolimus (AFINITOR) | Novartis Pharmaceuticals Australia Pty Limited | 26/07/10 | 5 mg and 10 mg tablets | For the treatment of tuberous sclerosis complex (TSC), including SEGA, angiomyolipoma and lymphangioleiomyomatosis (LAM) associated with TSC. |
| Everolimus (AFINITOR) | Novartis Pharmaceuticals Australia Pty Ltd | 30/03/12 | Tablets |
For the treatment of patients with tuberous sclerosis complex (TSC), including SEGA, angiomyolipoma and Lymphangioleiomyomatosis (LAM) associated with TSC. |
| Everolimus (AFINITOR) | Novartis Pharmaceuticals Australia Pty Ltd | 19/07/12 | Capsules |
For the treatment of pancreatic neuroendocrine tumours. |
| Ex vivo cultured adult human mesenchymal stem cells (PROCHYMAL) | Delpharm Consultants Pty Ltd | 08/11/10 | Solution for intravenous infusion | For the treatment of acute Graft versus Host Disease (aGvHD) in patients who have undergone Haematopoietic Stem Cell Transplantation (HSCT). |
| Extraneal brand of icodextrin 7.5% w/v peritoneal dialysis solution | Baxter Healthcare Pty Ltd | 26/09/01 | For use as an alternative osmotic agent in dialysis solutions for long dwell exchange in patients treated with peritoneal dialysis. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Factor eight inhibitor bypassing activity (FEIBA VH) | Baxter Healthcare Pty Ltd | 20/05/04 | For the treatment of haemophilia A patients with Factor VIII inhibitor and the treatment of hameophilia B patients with Factor IX inhibitor. | |
| Factor VIII[rDNA]; (KOGENATE FS, SF; HELIXATE FS, SF) | Bayer Australia Limited | 17/06/99 | For the treatment and prophylaxis of bleeding in haemophilia A (congenital factor VIII deficiency) in previously treated and untreated patients, and in patients with Factor VIII inhibitors (neutralising antibodies) who continue to respond to Kogenate FS (ie in whom haemostasis is achieved) [Kogenate FS does not contain von Willebrand's Factor and hence is not indicated in von Willebrand's disease]. | |
| Factor XI Concentrate (human coagulation factor XI) | CSL Behring (Australia) Pty Ltd | 12/12/14 | Powder for injection |
For the treatment and prevention of bleeding in patients with either congenital factor XI deficiency or acquired factor XI inhibitors. |
| Fedratinib | Sanofi-Aventis Australia Pty Ltd | Capsules | For the treatment of primary myelofibrosis, of post-polycythaemia vera myelofibrosis and of post-essential thrombocythaemia myelofibrosis. | |
| FEIBA NF factor eight inhibitor bypassing fraction 500U powder For injection vial with diluent vial | Baxter Healthcare Pty Ltd | 22/06/04 | Is indicated as second line therapy for the control of spontaneous bleeding episodes and use in surgery in haemophilia A or B patients with inhibitors, for whom recombinant human factor VIIa has failed, is contraindicated or has been associated with unacceptable adverse effects. | |
| Fingolimod (GILENYA, FILOSIR & FYNEFTA) | Novartis Pharmaceuticals Australia Pty Ltd | 24/11/14 | Capsule |
For the treatment of patients with Primary Progressive Multiple Sclerosis (PPMS) to delay the progression of physical disability. |
| Fluocinolone acetonide intravitreal implant (RETISERT) | Bausch & Lomb (Australia) Pty Ltd | 12/12/05 | For treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye. | |
| Fomepizole (TBA) | AFT Pharmaceuticals Pty Ltd | 06/01/15 | Injection |
For the treatment of ethylene glycol and methanol poisonings. |
| Fomivirsen sodium (VITRAVENE) | Ciba Vision Australia Pty Ltd | 01/04/99 | For the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency (AIDS). | |
| Forodesine (FOSODINE) | Mundipharma Pty Ltd | 24/03/09 | 100mg tablets and 5 mg/mL solution for injection | For the treatment of cutaneous T-cell lymphoma (CTCL). |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| G17 DT Immunogen | Orion Clinical Services (Australia) Ptd Ltd | 29/11/02 | Intramuscular injection |
For the treatment of gastric and pancreatic cancers. |
| G17DT (IMMUNOGEN) | Kendle R & D Pty Ltd | 20/11/03 | For the treatment of gastric and pancreatic cancers. | |
| Galsulfase rch (NAGLAZYME) | Cedarglen Investments Pty Ltd | 18/01/06 | Solution for injection | For long-term enzyme replacement therapy in the treatment of patients with mucopolysaccharidosis type VI (MPS VI). |
| Gemtuzumab ozogamicin (MYLOTARG) | Wyeth Australia Pty Ltd | 25/10/00 | For the treatment of acute myeloid leukaemia. | |
| GENOTROPIN brand of somatropin (rbe) | Pfizer Australia Pty Ltd | 09/02/07 | Powder for injection | For the treatment of growth disturbance in children with chronic renal insufficiency. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Histamine dihydrochloride | FH Faulding and Co Limited | 25/10/00 | For the treatment of metatastic melanoma (stage IV). | |
| Human fibrinogen (RIASTAP) | CSL Limited | 15/05/09 | Powder for injection by intravenous infusion | For the treatment of congenital fibrinogen deficiency. |
| Human hepatitis B immunoglobulin (HEPATECT CP) | Bioregulatory Consulting | 03/06/10 | Solution for intravenous infusion | Prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of the hepatitis B virus. |
| Human hepatitis B immunoglobulin (HEPATECT CP) | Link Medical Products Pty Ltd | 27/08/09 | Prophylaxis against re-infection of a transplanted liver in patients who carry the surface antigen of hepatitis B virus. | |
| Human plasma-derived protein C (CEPROTIN) | Baxter Healthcare Pty Ltd | 23/01/03 | For the treatment of severe congenital protein C deficiency. | |
| Humatrope brands of somatropin powder for subcutaneous or intramuscular injection | Eli Lilly Australia Pty Ltd | 13/06/02 | For the treatment of growth failure in children born small for gestational age. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Ibuprofen (PEDEA) | Emerge Health Pty Ltd | 29/05/13 | Solution for Injection | For the treatment of haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. |
| Icatibant (FIRAZYR) | Shire Australia Pty Ltd | 10/10/13 | Solution for injection | Treatment of angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema. |
| Icatibant (FIRAZYR) | Shire Australia Pty Ltd | 12/02/09 | 30mg/3mL pre-filled syringe | For the treatment of acute attacks of hereditary angioedema. |
| Icodextrin 7.5% (EXTRANEAL PERITONEAL DIALYSIS SOLUTION) | Baxter Healthcare Pty Ltd | 16/10/98 | For the treatment of life threatening, End Stage Renal Disease, for those patients who have been identified as requiring the specialised treatment of peritoneal dialysis, and who have subsequently demonstrated significantly reduced ultrafiltration with intraperitoneal hyperosmolar glucose. | |
| Idebenone (RAXONE) | TudorRose Consulting Pty Ltd | 24/08/16 | Film coated tablet |
for the treatment of Duchenne muscular dystrophy |
| Idebenone (RAXONE) | JACE Pharma Pty Ltd | 27/02/17 | Tablet, film-coated |
For the treatment of Duchenne muscular dystrophy (DMD). |
| Iloprost trometamol (ILOMEDIN) | Schering P/L | 13/10/00 | For the treatment of primary pulmonary hypertension. | |
| Imatinib mesylate (GLIVEC) | Novartis Australia Pty Ltd | 12/05/11 | Tablets and capsules | For the treatment of pulmonary arterial hypertension. |
| Imatinib mesylate (GLIVEC) | Novartis Pharmaceuticals Australia Pty Limited | 12/08/02 | For the treatment of chronic myeloid leukaemia. | |
| Imatinib mesylate (GLIVEC) | Novartis Pharmaceuticals Australia Pty Limited | 10/12/01 | For the treatment of adult patients with unresectable and/or metastatic malignant gastrointestinal stromal tumours. | |
| Imatinib mesylate (GLIVEC) | Novartis Pharmaceuticals Australia Pty Limited | 01/10/08 | 5 mg & 100 mg capsules and 100 mg & 400 mg tablets | For use as adjuvant therapy For gastrointestinal stromal tumour (GIST). |
| Imatinib mesylate (GLIVEC) | Novartis Pharmaceuticals Australia Pty Limited | 03/05/06 |
For the treatment of: |
|
| Imiglucerase (CEREZYME) | Genzyme Australasia Pty Ltd | 16/10/98 | For enzyme replacement for patients with a confirmed diagnosis of Gaucher's disease. | |
| Immunoglobulin - antithymocyte (rabbit) (ATG-Fresenius) | Dutec Diagnostics Pty Ltd | 18/06/10 | Solution for intravenous injection |
For the prevention of graft versus host disease in allogeneic haematopoietic stem cell transplantation. |
| Indinavir sulfate (CRIXIVAN) | Merck Sharp & Dohme (Australia) Pty Ltd | 03/10/00 | For the treatment of HIV-1 infection in children and adolescents over the age of 3 years. | |
| Infliximab | Schering-Plough Pty Ltd | 12/10/05 | For reducing the signs and symptoms in patients with moderately to severely active polyarticular-course juvenile rheumatoid arthritis (JRA) who have had an inadequate response to methotrexate. | |
| Inotuzumab Ozogamicin (BESPONSA) | Pfizer Australia Pty Ltd | 19/12/16 | Powder for injection |
For the treatment of B-cell acute lymphoblastic leukaemia (ALL). |
| Isavuconazonium sulfate | JACE Pharma Pty Ltd | 17/12/15 | Powder for injection and hard capsules |
For the treatment of invasive aspergillosis and invasive mucormycosis in patients 18 years of age and older. |
| Ivacaftor (KALYDECO) | Vertex Pharmaceuticals Australia Pty Ltd | 14/08/14 | Tablets |
For the treatment of cystic fibrosis (CF) in patients who have a CFTR mRNA Splice Site (Class V) mutation or a residual function CFTR mutation in the CFTR gene. |
| Ivacaftor (KALYDECO) | Vertex Pharmaceuticals Australia Pty Ltd | 14/03/12 | Tablets -film coated 150mg | For the treatment of cystic fibrosis (CF) in patients who have a gating or an R117H mutation in the CFTR gene. |
| Ivacaftor (KALYDECO) | Vertex Pharmaceuticals (Australia) Pty Ltd | 24/11/14 | Granules |
For the treatment of cystic fibrosis (CF) in patients aged 2 to 5 years old who have a gating (class III) or R117H, Residual or mRNA Splice Site (Class V) mutation in the CFTR gene. |
| Ivacaftor (VX-770) | Vertex Pharmaceuticals Australia Pty Ltd | 22/09/14 | Tablets |
In combination with Lumacaftor (VX-809) for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Lamivudine (ZEFFIX 3TCTM) | Glaxo Wellcome Australia Ltd | 11/01/01 | For use in combination with other antiretroviral agents for the treatment of HIV infection in children. | |
| Lamivudine (ZEFFIX) | GlaxoSmithKline Australia Pty Ltd | 19/06/02 | For the treatment of children (2 years and above) and adolescents with chronic hepatitis B and evidence of hepatitis B virus (HBV) replication. This indication is based on changes in serological and histological markers in clinical studies up to 18 months duration in patients with compensated liver disease. | |
| Lanreotide (SOMATULINE AUTOGEL) | Ipsen Pty Ltd | 19/03/04 | For the treatment of the symptoms of carcinoid syndrome associated with carcinoid tumours and the symptoms of VIPomas. | |
| Laronidase (ALDURAZYME) | Genzyme Australasia Pty Ltd | 08/08/01 | For the treatment of mucopolysaccharidosis. | |
| Leflunomide | Aventis Pharma Pty Ltd | 08/04/04 | For treatment of polyarticular course juvenile rheumatoid arthritis in patient 3 to 17 years of age. | |
| Lenalidomide (REVLIMID) | Celgene Pty Ltd | 28/01/15 | Capsule |
For the treatment of patients with mantle cell lymphoma. |
| Lenalidomide (REVLIMID) | Celgene Pty Ltd | 06/09/06 | Capsules | For the treatment of: previously treated multiple myeloma patients in combination with dexamethasone; and patients with transfusion-dependent anaemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality, with or without additional cytogenetic abnormalities. |
| Lenvatinib | Eisai Australia Pty Ltd | 14/07/17 | Hard capsules |
For the treatment of hepatocellular carcinoma. |
| Lenvatinib Mesilate | Eisai Australia Pty Ltd | 27/11/14 | Capsules |
For the treatment of patients with progressive, radioiodine - refractory differentiated thyroid cancer. |
| Lepirudin (REFLUDAN) | Celgene Pty Ltd | 09/10/08 | 50mg powder for injection | For the treatment of acute heparin associated thrombocytopenia (HAT) type II patients with thrombocytopenia or thromboembolic complications and for the prophylaxis of thrombocytopenia or new thromboembolic events in patients with a history of HAT type II and a need for effective antithrombotic measures (e.g. during open heart surgery). |
| Lepirudin (REFLUDAN) | Hoechst Marion Roussel | 16/10/98 | For the treatment of acute heparin associated thrombocytopenia (HAT) type II patients with thrombocytopenia or thromboembolic complications and for the prophylaxis of thrombocytopenia or new thromboembolic events in patients with a history of HAT type II and a need for effective antithrombotic measures (e.g. during open heart surgery). | |
| Letermovir (TBA) | Merck Sharp & Dohme (Australia) Pty Limited | 15/03/17 | Film coated tablet and powder for injection |
For the prevention of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) |
| Leuprorelin Acetate (LUCRIN) | AbbVie Pty Ltd | 19/12/12 | Injection | For the treatment of Central Precocious Puberty (CPP). |
| Leuprorelin Acetate (LUCRIN) | Abbott Australasia Pty Ltd | 22/07/11 | Injection |
For Central Precocious Puberty. |
| Linezolid (ZYVOX) | Pharmacia Australia Pty Ltd | 09/01/03 | For the treatment of children, from birth to less than 18 years, with suspected or proven infections due to organisms resistant to multiple classes of antibiotics, including methicillin resistant Staphylococcus species and vancomycin resistant Enterococcus species. | |
| Lonoctocog Alfa | CSL Behring Australia | 26/11/15 | Powder for reconstitution and injection. |
For the treatment in adults and children with haemophilia A (congenital FVIII deficiency) |
| Lumacaftor (VX-809) | Vertex Pharmaceuticals (Australia) Pty Ltd | 22/09/14 | Tablets |
In combination with Ivacaftor (VX-770) for the treatment of cystic fibrosis (CF) in patients who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| M-iodobenzyl [123I] guanidine injection (MIBGEN) | Australian Nuclear Science and Technology Organisation (ANSTO) | 15/08/02 | For: Diagnostic scintigraphic localisation of tumours originating in tissue that embryologically stems from the neural crest. These are neuroblastomas, pheochromocytomas, paragangliomas, chemodectomas and ganglioneuromas. Detection, staging and follow-up on therapy of neuroblastomas. Diagnosis of neural crest tumours, including those arising from the adrenal medulla, by evaluation of the uptake of iobenguane. | |
| Macitentan | Actelion Pharmaceuticals Australia Pty Ltd | 13/07/12 | Film coated tablets | For the treatment of pulmonary arterial hypertension. |
| Mannitol (BRONCHITOL) | Pharmaxis Ltd | 16/04/09 | 40mg powder for inhalation | For the treatment of patients with cystic fibrosis to improve lung function and reduce pulmonary exacerbations. |
| Mecasermin [rhIGF-1] injection (INCRELEX) 10mg/ml in 40 mg vial | Ipsen Pty Ltd | 01/07/08 | Solution for subcutaneous injection | For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like growth factor-1 deficiency (severe primary IGFD). |
| Melphalan (ALKERAN INJECTION) | Glaxo Wellcome Australia Ltd | 22/03/99 | For the treatment of multiple myeloma in patients For whom oral therapy is inappropriate. | |
| Mepolizumab (BOSATRIA) | GlaxoSmithKline Australia Pty Ltd | 17/03/08 | Powder for injection | For the treatment of patients with hypereosinophilic syndrome |
| Mepolizumab (Nucala) | GlaxoSmithKline Australia Pty Ltd | 11/05/17 | Powder for solution for injection |
For the treatment of patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). |
| Mercaptamine Hydrochloride (Cystadrops) | Emerge Health Pty Ltd | 17/07/15 | eye drops solution |
For the treatment of corneal cystine deposits in cystinosis in adults and children over two years of age. |
| Mercaptopurine | Ballia Holdings Pty Ltd | 14/12/12 | Oral suspension | For the treatment of Acute Lymphoblastic Leukaemia in Children. |
| Mercaptopurine (XALUPRINE) | Link Medical Products Pty Ltd | 15/08/12 | Oral suspension | For the treatment of Acute Lymphoblastic Leukaemia in paediatric patients. |
| Methotrexate | Ballia Holdings Pty Ltd | 14/12/12 | Oral suspension | For the treatment of Acute Lymphoblastic Leukaemia in Children. |
| Methoxsalen (UVADEX) | Terumo BCT Australia Pty Limited | 15/09/15 | Injection solution |
For the treatment of Cutaneous T- cell lymphomas (CTCL). |
| Methoxsalen (UVADEX) | Terumo BCT Australia Pty Ltd | 01/10/15 | Injection solution |
For the treatment of Graft-versus-host disease (GVHD) following allogeneic HSC transplantation. |
| Methoxsalen (UVADEX) | Terumo BCT Australia Pty Ltd | 01/10/15 | Injection solution |
For the treatment of Graft-versus-host disease (GVHD) following allogeneic HSC transplantation. |
| Midazolam (MIDAZOLAM BUCCAL LIQUID) | Phebra Pty Ltd | 01/06/09 | 10mg in 1mL liquid to be administered via an oral syringe into the buccal cavity | For the treatment of status epilepticus in children and adolescents aged 0 to 19 years. |
| Midostaurin (RYDAPT) | Novartis Pharmaceuticals Australia Pty Limited | 22/06/16 | Capsule |
For the treatment of adult patients with the following: |
| Mifamurtide (Mepact) | Nycomed Pty Ltd | 02/09/13 | Powder for infusion | |
| Migalastat hydrochloride (GALAFOLD) | ERA Consulting Australia Pty Ltd | 02/02/16 | Capsules for oral administration. |
For the long-term treatment of adult and adolescent patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) who have an amendable mutation. |
| Miglustat (ZAVESCA) | Actelion Pharmaceuticals Australia Pty Ltd | 11/07/05 | Capsules | For the treatment of mild to moderate type 1 Gaucher disease. |
| Miglustat (ZAVESCA) | Actelion Pharmaceuticals Australia Pty Ltd | 08/07/08 | Capsules | For the treatment of Niemann-Pick disease Type C. |
| Momelotinib dihydrochloride monohydrate | Gilead Sciences Pty Ltd | 31/07/17 | Film-coated tablets |
For the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. |
| Mometasone furoate | RhinoScience Pty Ltd | 14/09/11 | Irrigation base equivalent 2mg/240mL solution | For the treatment of persistent post-surgical eosinophilic polypoid chronic rhinosinusitis. |
| MultiBic | Fresenius Medical Care Australia Pty Ltd | 16/08/04 | For the treatment of acute renal failure in intensive care units. | |
| Mycophenolic acid (as sodium) MYFORTIC | Novartis Pharmaceuticals Australia Pty Limited | 11/01/10 | 180 mg and 360 mg enteric coated tablets | For induction and maintenance treatment of lupus nephritis. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| N-acetyl cysteine Omeprazole (NACO) | Jon Pty Ltd | 21/07/17 | Oral gelatine capsule containing dry powder formulation of 100 mg Omeprazole containing the stabiliser anti oxidant 250 mg N-Acetyl cysteine |
Treatment of cancers which have developed resistance to cationic therapies. Note: On 23 November 2017, the Administrative Appeals Tribunal designated N-acetyl cysteine Omeprazole (NACO) as an orphan drug pursuant to an agreement reached between the parties under section 42C of the Administrative Appeals Tribunal Act 1975 (AAT Act). The designation follows the decisions of the Minister's delegate and the Secretary's delegate not to designate NACO as an orphan drug. Pursuant to subsection 43(6) of the AAT Act, the designation takes effect from the date of the decision of the Minister's delegate, being 21 July 2017. |
| Nandrolone decanoate (DECA-DURABOLIN 100) | Organon | 30/12/99 | For patients who have proven HIV infection who have lost at least 5% of their usual body weight. | |
| Nanoparticle albumin-bound paclitaxel (ABRAXANE) | Abraxis BioScience Australia Pty Ltd | 01/12/09 | Powder for injection (suspension) | For treatment of pancreatic cancer. |
| Natalizumab (TYSABRI) | Biogen Idec Australia | 01/07/14 | Concentrated injection solution |
For the treatment of relapsing-remitting multiple sclerosis in children aged 10-17 years. |
| Nevirapine (VIRAMUNE) | Boehringer Ingelheim Pty Limited | 11/03/03 | For the prevention of mother to child transmission of HIV-1 in pregnant women who are not taking antiretroviral therapy at time of labour. | |
| Nilotinib (TASIGNA) | Novartis Pharmaceuticals Australia Pty Limited | 09/06/06 | 200mg capsules blister packs | For treatment of patients with chronic myeloid leukaemia. |
| Nitazoxanide (CRYPTAZ) | Tri-Med Distributors | 13/10/99 | For the treatment of patients with AIDS who are positive for a stool test for cryptosporidiosis. | |
| Nitisinone (Disanit) | Emerge Health Pty Ltd | 20/07/17 | Capsules 2mg 5mg and 10mg (stable capsule formulation) |
For the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. |
| Nitisinone (ORFADIN) | Orphan Australia Pty Ltd | 30/10/08 | 2mg, 5mg and 10mg capsules | For the treatment of hereditary tyrosinaemia type 1. |
| Nitisinone (ORFADIN) | A Menarini Australia Pty Ltd | 31/08/16 | Capsules and oral liquid suspension |
For the treatment of patients with hereditary tyrosinaemia type 1. |
| Nitric oxide (INOmax) | Delpharm Consultants Pty Ltd | 11/05/06 | 800 ppm medicinal gas for inhalation cylinder | For the treatment of Persistent Pulmonary Hypertension (PPH) in neonates. |
| Nitric Oxide (INOmax) | Ikaria Australia Pty Ltd | 11/09/13 | indication is inhalational gas | The indication is that it is indicated, in conjunction with ventilator support and other appropriate agents, as part of the treatment of peri-and post-operative pulmonary hypertension in newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction with heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation. |
| Normal immunoglobulin (human) (KIOVIG) | Baxter Healthcare Pty Ltd | 29/11/12 | Intravenous use injection | For the treatment of immunomodulatory therapy in multifocal motor neuropathy (MMN). |
| Normal immunoglobulin (INTRAGLOBIN F) | Medical Dynamics Australia (MDA) Pharma | 27/02/01 | For the treatment of: Primary Immune Deficiency Syndromes Kawasaki disease Paediatric HIV infection / Congenital AIDS Allogeneic Bone Marrow Transplantation Idiopathic Thrombocytopaenic Purpura. | |
| NOVOSEVEN brand of eptacog alfa (activated) bhk | Novo Nordisk Pharmaceuticals Pty Ltd | 30/01/07 | Powder for injection | For the treatment of postpartum haemorrhage in patients unresponsive to standard obstetrical management, oxytocic drugs and standard blood component therapy prior to major invasive therapy. |
| NSC-631570 (UKRAIN) | Mrs Aleksandra Harasemcuk | 08/06/04 | For the treatment of pancreatic cancer. | |
| Nusinersen | Biogen Australia Pty Ltd. | 21/04/16 | Solution for injection (intrathecal injection). |
For the treatment of Spinal Muscular Atrophy (SMA). |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Obeticholic Acid | AU Pharma Pty Ltd | 21/04/17 | Tablets |
For the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA. |
| Oblimersen (GENASENSE) | Aventis Pharma Pty Ltd | 25/09/03 | For the treatment of patients with stage IV malignant melanoma. | |
| Oblimersen (GENASENSE) | ICON Clinical Research | 10/01/08 | Solution for infusion | For the treatment of patients with stage IV malignant melanoma. |
| Oblimersen (GENASENSE) | Kendle R & D Pty Ltd | 24/11/06 | For the treatment of patients with stage IV malignant melanoma. | |
| Octocog alfa rch (ADVATE) intravenous injection | Baxter Healthcare Pty Ltd | 19/02/07 | Is indicated for use in haemophilia A for prevention and control of haemorrhagic episodes. | |
| Octocog alfa rch (ADVATE) powder for injection vials with diluent | Baxter Healthcare Pty Ltd | 10/03/04 | Is indicated for use in haemophilia A for prevention and control of haemorrhagic episodes. | |
| Octreotide (SANDOSTATIN / SANDOSTATIN LAR) | Novartis Pharmaceuticals Australia Pty Limited | 15/05/09 | · 500 microgram/1mL injection ampoule · 50 microgram/1mL injection ampoule · 100 microgram/1mL injection ampoule · 10mg injection vial plus diluent prefilled syringe composite pack · 20mg injection vial plus diluent prefilled syringe composite pack and; · 30mg injection vial plus diluent prefilled syringe composite pack | For treatment of patients with symptoms associated with: · functional gastro-entero-pancreatic neuroendocrine tumours (GEP/NETs); · Glucagonomas; · Gastrinomas/Zollinger-Ellison syndrome; · Insulinomas, for pre-operative control of hypoglycaemia and for maintenance therapy; and · GRFomas. |
| Octreotide (SANDOSTATIN LAR) | Novartis Pharmaceuticals Australia Pty Limited | 15/09/10 | 10, 20 and 30 mg prefilled syringe composite packs | For the treatment of patients with advanced neuroendocrine tumours of the midgut or unknown primary tumour location. |
| Olaparib | AstraZeneca Pty Ltd | 15/01/14 | Capsule | Is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapse BRCA-mutated ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. |
| Oprelvekin (IL-11) (NEUMEGA) | Wyeth Australia Pty Ltd | 07/04/99 | For the prevention of severe chemotherapy-induced thrombocytopenia (SCIT) in patients with non-myeloid malignancies who are judged by their physician to be at risk of severe thrombocytopenia. | |
| Ovine anti-colchicine polyclonal antibody fragments (COLCHIFAB) | Microfarm Limited | 04/07/11 | Ampoules | As an antidote in cases of acute colchinine toxicity. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Panobinostat (FARYDAK) | Novartis Pharmaceuticals Australia Pty Ltd | 21/01/14 | Capsule |
For the treatment of patients with relapsed multiple myeloma (MM), or relapsed-and-refractory MM. |
| Panobinostat (TBA) | Novartis Pharmaceuticals Australia Pty Limited | 24/03/09 | Capsules | For the treatment of cutaneous T-cell lymphoma (CTCL). |
| Para-aminosalicylic acid (PASER) | Link Medical Products Pty Ltd | 11/02/15 | Enteric coated granules |
For use as part of an appropriate combination therapy for the treatment of multi-drug resistant tuberculosis. |
| Pasireotide (SIGNIFOR LAR) | Novartis Pharmaceuticals Australia Pty Limited | 29/10/13 | Modified release injection | For the treatment of patients with Acromegaly for whom medical therapy is appropriate. |
| Pasireotide (SIGNIFor) | Novartis Pharmaceuticals Australia Pty Limited | 03/08/11 | Solution for injection | For the treatment of patients with Cushing's disease for whom medical therapy is appropriate. |
| Pazopanib (PATORMA) | GlaxoSmithKline Australia Pty Ltd | 24/03/09 | 200mg and 400mg film coated tablets | For the treatment of advanced and/or metastatic renal cell carcinoma (RCC). |
| Pazopanib (VOTRIENT) | GlaxoSmithKline Australia Pty Ltd | 13/05/11 | Tablets | For the treatment of advanced (unresectable and/or metastatic) soft tissue sarcoma. |
| PEDITRACE and ADDAMEL N brands of trace element solutions for intravenous injection | Fresenius Medical Care Australia Pty Ltd | 08/11/01 | For the supply of basal trace element requirements in infants/children and adults, respectively. | |
| Pegaspargase (ONCASPAR) | Baxalta Australia Pty Ltd | 06/04/16 | Solution for injection |
For the treatment of patients with Acute Lymphoblastic Leukaemia |
| Pegaspargase (ONCASPAR) | Link Medical Products | 24/04/15 | Solution for injection |
For the treatment of patients with acute lymphoblastic leukaemia (ALL). |
| Pegaspargase (PEGASPAR) | Rhone-Poulenc Rorer Australia | 20/01/99 | For the treatment of patients with acute lymphoblastic leukaemia who require L-asparaginase in their treatment regimen, but have developed hypersensitivity to the native forms of L-asparaginase. | |
| Peginterferon alfa-2a and ribavirin (PEGASYS RBV) | Roche Products Pty Ltd | 15/06/12 | Injection | For the treatment of chronic hepatitis C in treatment-naïve children and adolescents 5 years of age and older with compensated liver disease. |
| Peginterferon alfa-2b and ribavirin (PEGATRON COMBINATION THERAPY) | Schering-Plough Pty Ltd | 15/01/10 | Peginterferon alfa-2b; 50, 80, 100, 120 and 150 microgram powder for injection and ribavirin 200 mg capsule. | For the treatment of chronic hepatitis C in children = 27 kg with compensated liver disease and who have not received previous interferon treatment. |
| Pegvisomant (rbe) (SOMAVERT) | Pharmacia Australia Pty Ltd | 09/10/03 | Powder for injection with diluent | For the treatment of patients with acromegaly. |
| Pegylated liposomal doxorubicin (CAELYX) | Schering-Plough Pty Ltd | 05/07/07 | Injection vial 20 ml/10mL and 50mg/25mL | For use, in combination, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have undergone or are unsuitable for bone marrow transplantation. |
| Pegylated liposomal doxorubicin hydrochloride (CAELYX) | Schering-Plough Pty Ltd | 28/02/00 | For the treatment of advanced ovarian cancer in women who have failed first-line platinum-based chemotherapy. | |
| Pentostatin (NIPENT) | Hospira Australia Pty Ltd | 15/05/09 | 10mg powder for injection and powder for solution for infusion | For the treatment of Hairy Cell Leukaemia (HCL) |
| Peritoneal dialysis solution (GAMBROSOL BIO) | Gambro | 23/12/99 | For the treatment of patients receiving peritoneal dialysis who may need to change from peritoneal dialysis because of decreased ultrafiltration or infusion pain. | |
| Peritoneal dialysis solution with 1.1% amino acids (Nutrineal-PD4) | Baxter Healthcare Pty Ltd | 04/03/99 |
For the treatment of protein malnutrition in patients with End Stage Renal Disease (ESRD) who are maintained by peritoneal dialysis. |
|
| Pertuzumab | Roche Products Pty Ltd | 19/01/12 | Concentrate for intravenous infusion | For the treatment of patients with HER-2 positive metastatic (Stage IV) or locally recurrent breast cancer. |
| PHYSIONEAL 40 brand of peritoneal dialysis solutions containing 13.6mg/mL, 22.7mg/mL or 38.7mg/mL glucose | Baxter Healthcare Pty Ltd | 08/05/02 | For peritoneal dialysis. | |
| Piracetam (NOOTROPIL) | UCB Pharma | 04/05/00 | as "add-on" treatment of cortical myoclonus. | |
| Plerixafor (MOZOBIL) | Genzyme Australasia Pty Ltd | 20/10/08 | Injection | For the mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent transplantation. |
| Pomalidomide | Celgene Pty Ltd | 17/10/12 | Capsules | For the treatment of multiple myeloma in patients who have failed two or more prior therapies. |
| Ponatinib (tradename TBA) | ARIAD Pharmaceutical (Australia) Pty Ltd | 14/05/13 | 15mg and 45mg immediate film coated tablets | For the treatment of acute lymphoblastic leukaemia and adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. |
| Poractant alfa (CUROSURF) | Douglas Pharmaceuticals Australia Ltd | 11/04/03 | For the treatment of Respiratory Distress Syndrome (RDS) in preterm infants and for prophylactic use in preterm infants at risk for RDS. | |
| Pralatrexate (FOLOTYN) | Mundipharma Pty Ltd | 05/09/11 | Solution for Injection | For the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (nodal, extranodal and leukaemic/disseminated). |
| Pralidoxime chloride | Ophthalmic Laboratories Pty Ltd (T/A Pharmalab) | 03/05/06 | For the treatment of poisoning due to those pesticides and chemicals of the organophosphate class which have anticholinesterase activity and the control of overdosage of the anticholinesterase drugs used in the treatment of myasthenia gravis. | |
| Propranolol hydrochloride | Pierre Fabre Medicament Australia Pty Ltd | 03/10/12 | Oral solution | For the treatment of proliferating infantile hemangiomas requiring systemic therapy. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Rabies immunoglobulin Pasteurised (IMOGAM RAGE) | CSL Limited | 16/10/98 | To treat subjects who are thought to have been exposed to rabies virus, especially cases of major exposure, in accordance with WHO recommendations. | |
| Raltegravir (ISENTRESS) | Merck Sharp & Dohme (Australia) Pty Ltd | 05/09/11 | Tablet | Treatment of HIV-1 infection in children and adolescents from 2 to 18 years of age. |
| Ramucirumab (Cyramza) | Eli Lilly Australia Pty Ltd | 17/09/13 | Solution for infusion | The indication is for the treatment of patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after prior chemotherapy. |
| Ranpirnase (ONCONASE) | Delpharm Consultants Pty Ltd | 22/03/05 | For the treatment of malignant mesothelioma. | |
| Rasburicase (FASTURTEC) | Sanofi-Synthelabo Aust Pty Ltd | 23/03/01 | For the treatment and prophylaxis of acute hyperuricaemia in patients with haematological malignancy at risk of a rapid tumour lysis. | |
| Recombinant factor IX (BENEFIX) | Wyeth Australia Pty Ltd | 16/10/98 | For the control and prevention of haemorrhagic episodes and for routine and surgical prophylaxis in patients with haemophilia B (congenital factor IX deficiency or Christmas disease). | |
| Recombinant factor IX (FIXTERA) | Baxter Healthcare Pty Ltd | 03/10/12 | IV injection | For the treatment of the control and prevention of haemorrhagic episodes and for routine and surgical prophylaxis in patients with haemophilia B (congenital factor IX deficiency or Christmas disease). |
| Recombinant factor VIII (ADVATE) | Baxter Healthcare Pty Ltd | 10/03/03 | For the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). | |
| Recombinant factor VIII(rDNA)(cho) (REFACTO) | Wyeth Australia Pty Ltd | 18/01/99 | For the control and prevention of haemorrhagic episodes and for routine and surgical prophylaxis in patients with haemophilia A (congenital factor VIII deficiency or classical haemophilia). | |
| Recombinant human coagulation factor IX Fc fusion protein (rFIXFc) | Biogen Idec Australia Pty Ltd | 20/09/12 | Lyophilised powder for reconstitution IV injection | For the treatment of the control and prevention of haemorrhagic episodes in patients with haemophilia B (congenital factor IX deficiency or Christmas disease), including the control and prevention of bleeding in surgical settings. |
| Recombinant human coagulation factor VIII Fc fusion protein | Biogen Idec Australia Pty Ltd | 22/02/13 | Lyophilized powder for reconstitution IV injection | For the treatment of control and prevention (including routine prophylaxis) of bleeding episodes in adults and children with haemophilia A. |
| Recombinant human iduronate-2-sulfatase (IDURSULFASE) | Genzyme Australasia Pty Ltd | 18/01/06 | For long-term treatment of patients with Hunter syndrome | |
| Regorafenib (STIVARGA) | Bayer Australia Ltd | 13/07/16 | Tablet |
For the treatment of hepatocellular carcinoma. |
| Retroviral γc cDNA-containing vector (IMMUGENE) | AVAX Australia Pty Ltd | 21/08/02 | For the treatment of severe combined immunodeficiency X1 (SCID X1). Status: The orphan drug designation for this product was withdrawn on 2 October 2002. | |
| RidaForolimus (JENZYL) | Merck Sharp & Dohme (Australia) Pty Ltd | 14/09/11 | Gastro resistant tablet | Treatment of metastatic soft tissue sarcoma or bone sarcoma. |
| Rifaximin (XIFAXAN) | Norgine Pty Ltd | 24/02/11 | Tablets | For the prevention of the recurrence of Hepatic Encephalopathy in adults. |
| Riluzole (RILUTEK) | Aventis Pharma Pty Ltd | 03/05/01 | For the treatment of amyotrophic lateral sclerosis (ALS). | |
| Riluzole (TEGLUTIK) | Seqirus Pty Ltd | 13/02/17 | Liquid - oral suspension |
For the treatment of patients with amyotrophic lateral sclerosis (ALS). |
| Riociguat | Bayer Australia Limited | 16/10/12 | Immediate - release tablets | For the treatment of Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) |
| Rituximab (MabThera) | Roche Products Pty Ltd | 13/10/11 | Intravenous infusion | Induction of remission in patients with severely active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. |
| Romidepsin (ISTODAX) | Celgene Pty Ltd | 27/08/10 | 10 mg powder for injection | For the treatment of: · patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic therapy; and · patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. |
| Romiplostim (Nplate) | Amgen Australia Pty Ltd | 20/06/17 | powder for Injection |
For the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP). |
| Rovalpituzumab Tesirine (TBA) | AbbVie Pty Ltd | 20/05/17 | Lyophilised powder for injection |
For the treatment of small cell lung cancer |
| Rufinamide | Eisai Australia Pty Ltd | 23/09/16 | Tablets and oral suspension |
For the treatment of seizures associated with Lennox-Gastaut syndrome. |
| Ruxolitinib (JAKAVI) | Novartis Pharmaceuticals Australia Pty Ltd | 16/10/14 | Tablet |
For the treatment of patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea. |
| Ruxolitinib (JAKAVI) | Novartis Pharmaceuticals Australia Pty Limited | 23/04/12 | Tablets | For the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelobfibrosis. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Sapropterin dihydrochloride | Serono Pty Ltd | 30/08/06 | Oral tablet | For treatment of patients with hyperphenylalaninemia. |
| Sebelipase Alfa | Alexion Pharmaceuticals Australasia Pty Ltd | 14/11/15 | solution for injection |
For the treatment of lysosomal acid lipase (LAL) deficiency |
| Selexipag | Actelion Pharmaceuticals Australia Pty Ltd | 25/09/14 | Tablet |
For the treatment of pulmonary arterial hypertension. |
| Siltuximab (Sylvant) | Janssen-Cilag Pty Ltd | 14/08/14 | Powder for infusion |
Treatment of adults with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative. |
| Sirolimus | Wyeth Australia Pty Ltd | 26/03/07 | Tablets 1 mg, 2 mg and 5 mg and oral solution (1 mg/mL, 60 mL) | For the prevention of coronary allograft vasculopathy. |
| Sodium Benzoate (PROHIPPUR) | Orpharma Pty Ltd | 06/12/16 | Granules |
For the the treatment of Nonketotic hyperglycinaemia (NKH) |
| Sodium Benzoate (Prohippur) | Orpharma Pty Ltd | 06/12/16 | Granules |
for the treatment of: |
| Sodium phenylbutrate (PHEBURANE) | Orpharma Pty Ltd | 13/08/14 | Granules |
Treatment of urea cycle disorders. |
| Sodium Phenylbutyrate | Orpharma Pty Ltd | 22/03/17 | Tablet |
For the treatment of urea cycle disorders. |
| Somatropin (HUMATROPE PENFIL) | Aza Research | 10/06/99 | For the treatment of growth retardation in pre-pubertal children with chronic renal insufficiency. | |
| Somatropin (rbe) (GENOTROPIN) | Pharmacia & Upjohn | 08/05/00 | For improvement of body composition and treatment of short stature in patients with Prader-Wili syndrome. | |
| Somatropin (rbe) (NORDITROPIN SIMPLEXX and NORDITROPIN NORDIFLEX) | Novo Nordisk Pharmaceuticals Pty Ltd | 08/05/09 | Injection-solution multidose cartridges | For the treatment of prader-willi syndrome, for improvement of growth and body composition. |
| Somatropin (rbe) recombinant human growth hormone (GENOTROPIN) | Pharmacia Australia Pty Ltd | 28/11/01 | For treatment of growth disturbance in pre-pubertal children with chronic renal insufficiency. | |
| Somatropin (rbe) recombinant human growth hormone (GENOTROPIN) | Pharmacia Australia Pty Ltd | 02/11/01 | For treatment of growth failure children born small for gestational age. | |
| Somatropin (rbe) recombinant human growth hormone (NORDITROPIN, NORDITROPIN PENSET 12 and 14, NORDITROPIN SIMPLEXX) | Novo Nordisk Pharmaceuticals Pty Ltd | 11/03/02 | For treatment of severe growth failure due to intrauterine growth retardation (i.e. children born small for gestational age without spontaneous catch up growth by 2 years of age and height below -3SD at start of treatment). | |
| Somatropin (rbe) recombinant human growth hormone (NORDITROPIN, NORDITROPIN SIMPLEXX) | Novo Nordisk Pharmaceuticals Pty Ltd | 22/05/02 | For treatment of severe growth failure due to intrauterine growth retardation (i.e. children born small for gestational age without spontaneous catch up growth by 2 years of age). | |
| Somatropin (SAIZEN) | Merck Serono Australia Pty Ltd | 05/09/11 | Growth disturbance in pre-pubertal children with chronic renal insufficiency. | |
| Sorafenib (NEXAVAR) | Bayer Australia Limited | 04/03/13 | Tablet | For the treatment of patients with radioactive iodine treatment (RAI) refractory, locally advanced or metastatic differentiated thyroid cancer (DTC). |
| Stay Safe Balance and Sleep Safe Balance range of sterile peritoneal dialysis solutions | Fresenius Medical Care Australia Pty Ltd | 21/08/02 | For the management of end stage renal disease and acute renal failure. | |
| Stiripentol (DIACOMIT) | Emerge Health Pty Ltd | 23/06/16 | Capsule and oral powder |
For the treatment of severe myoclonic epilepsy in infancy (SMEI also known as Dravet syndrome). |
| Sunitinib malate (SUTENT) | Pfizer Australia Pty Ltd | 04/05/10 | 12.5 mg, 25 mg, 37.5 mg and 50 mg capsules | For the treatment of pancreatic neuroendocrine tumours (pNET). |
| Susoctocog alfa | Baxter Healthcare Pty Ltd | 03/07/14 | Powder for injection |
For the treatment and prevention of serious bleeding episodes in patients with acquired haemophilia A. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Tacrolimus (PROGRAF) | Janssen-Cilag Pty Ltd | 22/10/03 | For use as an immunosuppressant in lung transplantation. | |
| Tacrolimus (PROGRAF) | Janssen-Cilag Pty Ltd | 06/09/06 | 0.5, 1 and 5 mg capsules and a 5 mg/mL concentrate for intravenous infusion | For use as an immunosuppressant in heart transplantation. |
| Tadalafil (ADCIRCA) | Eli Lilly Australia Pty Ltd | 21/04/10 | 20mg tablets | For the treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability. |
| Tafamidis meglumine (VYMDAQEL) | Pfizer Australia Pty Ltd | 22/07/11 | 20mg soft gelatine capsules | For the oral treatment of Transthyretin Amyloidosis in adult patients with Symptomatic Polyneuropathy. |
| Tafenoquine | GlaxoSmithKline Australia Pty Ltd | 21/04/17 | Tablet |
For the radical cure (prevention of relapse) of Plasmodium vivax malaria. |
| Taliglucerase (ELELYSO) | Pfizer Australia Pty Ltd | 11/03/11 | Powder for injection | For the treatment of Gaucher's Disease |
| Teduglutide (REVESTIVE) | Shire Australia Pty Ltd | 13/06/17 | Powder for solution for injection |
For the treatment of paediatric patients with Short Bowel Syndrome who are dependent on parenteral support. |
| Teduglutide (REVESTIVE) | Shire Australia Pty Limited | 16/12/15 | Solution for injection |
For the treatment of adult patients with Short Bowel Syndrome (SBS) who are dependent on parenteral support. |
| Telotristat etiprate | Ipsen Pty Ltd | 29/07/16 | Film coated tablet |
For the treatment of Carcinoid Syndrome. |
| Temozolomide (TEMODAL) | Schering-Plough Pty Ltd | 24/07/03 |
For treatment of: |
|
| Temozolomide (TEMODAL) | Schering-Plough Pty Ltd | 21/09/04 | For the treatment of patients with newly diagnosed anaplastic astrocytoma and gioblastoma multiforme. | |
| Temsirolimus (TORISEL) | Wyeth Australia Pty Ltd | 17/03/08 | Concentrate for injection | For the treatment of patients with mantle cell lymphoma. |
| Tenofovir disoproxil fumarate (VIREAD) | Gilead Sciences Pty Ltd | 13/10/09 | Oral powder (40mg/1 g) and tablet (300mg) | In combination with other antiretroviral agents for the treatment of HIV-infected patients 2 to 17 years of age. |
| Terlipressin (GLYPRESSIN) | Ferring Pharmaceuticals Pty Ltd | 21/01/04 | · Freeze dried powder (1 mg/vial) with diluent (5 mL/ ampoule) and; · solution (0.12 mg/ mL ampoule) | For the treatment of bleeding oesophageal varices and for the treatment of hepatorenal syndrome. |
| Terlipressin acetate (LUCASSIN) | Ikaria Australia Pty Ltd | 25/06/10 | Powder for injection | For the treatment of: · patients with hepatorenal syndrome type 1 (HRS-1);and · oesophageal variceal haemorrhage (OVH). |
| Thalidomide (THALIDOMIDE PHARMION) | Celgene Pty Ltd | 10/10/08 | 50mg hard capsules | For the treatment of relapsing or refractory multiple myeloma and erythema nodosum leprosum or Type II lepra reactions. |
| Thalidomide (THALOMID) | Pharmion Pty Ltd | 13/03/02 | For the treatment of: · erythema nodosum leprosum or Type II lepra reactions; and · relapsing or refractory multiple myeloma. | |
| Thiotepa (TEPADINA) | Helex-A Pty Ltd | 23/02/16 | Powder for injection |
For the conditioning treatment prior to haematopoietic progenitor cell transplantation. |
| Thymoglobuline (rabbit anti-human thymcoyte immunoglobulin) | Genzyme Australasia Pty Ltd | 22/02/07 | Powder for injection | For the treatment of: · prophylaxis and treatment of graft rejection in renal transplantation; · prophylaxis of graft rejection in heart transplantation and; · aplastic anaemia. |
| Thyroptropin alfa-rch powder for injection | Genzyme Australasia Pty Ltd | 24/01/05 | For therapeutic use in post-thyroidectomy patients maintained on hormone suppression therapy in the ablation of thyroid remnant tissue in combination with radioactive iodine. | |
| Thyrotropin alfa (THYROGEN) | Genzyme Australasia Pty Ltd | 07/10/99 | For use with radioactive iodine imaging and serum thyroglobulin (Tg) testing, undertaken for the detection of thyroid remnants and well-differentiated thyroid cancer in post-thyroidectomy patients maintained on hormone suppression therapy and at risk of recurrence. | |
| Tipifarnib (ZARNESTRA) | Janssen-Cilag Pty Ltd | 17/11/04 | For the treatment of acute myeloid leukaemia. | |
| Tobramycin | Boucher & Muir Pty Ltd | 10/02/16 | Solution for inhalation |
For the treatment of cystic fibrosis patients infected with Pseudomonas aeruginosa. |
| Tobramycin (TOBI) | Novartis Pharmaceuticals Australia Pty Limited | 08/11/10 | Powder for inhalation | For the treatment of cystic fibrosis patients infected with Pseudomonas aeruginosa. |
| Tobramycin (TOBI)solution for inhalation | Pathogenesis Corporation | 29/09/98 | For the treatment of cystic fibrosis patients infected with Pseudomonas aeruginosa. | |
| Tobramycin sulfate | Ophthalmic Laboratories Pty Ltd (T/A Pharmalab) | 28/04/06 | For treatment of patients with cystic fibrosis infected with Pseudomonas species. | |
| Tobramycin sulfate solution for inhalation | Ophthalmic Laboratories Pty Limited | 18/06/04 | For the treatment of patients with cystic fibrosis infected with Pseudomonas species. | |
| Tracleer (BOSENTAN) | Actelion Pharmaceuticals Australia Pty Ltd | 04/10/05 | For the treatment of Primary Pulmonary Arterial Hypertension (WHO Class PH I) in patients with WHO Functional Class III or IV symptoms. | |
| Trametinib | GlaxoSmithKline Australia Pty Ltd | 01/06/12 | Tablets | For the treatment of the patients with BRAF V600 mutation positive unresectable or metastatic (Stage IV) melanoma. |
| Trastuzumab emtansine (RCH) | Roche Products Pty Ltd | 02/05/12 | Powder | For the treatment of HER-2 positive breast cancer patients who have locally recurrent, locally advanced or metastatic (Stage IV) disease. |
| Tremelimumab | AstraZeneca | 26/11/15 | Solution for infusion |
For the treatment of malignant mesothelioma. |
| Treprostinil (REMODULIN) (incorrectly gazetted as epoprostenol) | Orphan Australia Pty Ltd | 29/05/01 | For the treatment of pulmonary arterial hypertension. | |
| Tumour necrosis factor alpha 1-a (BEROMUN) | Boehringer Ingleheim (Australia) Pty Ltd | 21/10/98 | As an adjunct to surgery for subsequent removal of the tumour (soft tissue sarcoma) so as to delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in conjunction with melphalan in hyperthermic isolated limb perfusion. | |
| Turoctocog alpha (RCH) | Novo Nordisk Pharmaceuticals Pty Ltd | 04/09/12 | Powder for solution for injection. | For the treatment and prophylaxis of bleeding episodes in patients with haemophilia A. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Vandetanib (brand name yet to be advised) | AstraZeneca Pty Ltd | 15/09/10 | Tablets | For the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer. |
| Velaglucerase alfa | Shire Australia Pty Ltd | 08/12/09 | Powder for solution for injection | For the treatment of Gaucher disease. |
| Vemurafenib | Roche Products Pty Ltd | 14/04/11 | Tablets | For the treatment of unresectable Stage IIIC or Stage IV metastatic melanoma whose tumours harbour the BRAF mutation. |
| Vinflunine ditartrate (JAVLOR) | Pierre Fabre Australia | 21/01/15 | Injection |
For the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. |
| Vorinostat (ZOLINZA) | Merck Sharp & Dohme (Australia) Pty Ltd | 21/10/08 | Capsules | For the treatment of patients with advanced cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease subsequent to prior systemic therapy. |
| VX-770 | Voisin Consulting Australia Pty Ltd | 15/06/10 | 100 mg and 150 mg film coated tablet | For improving pulmonary function in cystic fibrosis patients with at least one allele with a G551D-CF transmembrane conductance regulator gene (CFTR) mutation or homozygous for F508del-CFTR mutation. |
| Drug | Sponsor | Date of designation | Dose | Indication |
|---|---|---|---|---|
| Zanolimumab | Merck Serono Australia Pty Ltd | 10/07/07 | Solution for infusion at 20 mg/mL | For the treatment of patients with cutaneous T cell lymphoma. |
| Zemaira Brand of alpha proteinase inhibitor (Human) | CSL Limited | 08/08/07 | Powder for injection | For the treatment of chronic intravenous augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema. |
| Zoledronic acid (ZOMETA) | Novartis Pharmaceuticals Australia Pty Limited | 08/05/09 | 4 mg powder for injection and 4 mg/5 mL concentrated injection | For the treatment of paediatric patients with severe osteogenesis imperfecta (OI). |
- Category:Prescription medicines
- Tags:orphan drugs
- URL:https://www.tga.gov.au/node/3390